发稿单位：
Science Direct
发稿时间：
Received 26 February 2020,
Accepted 27 February 2020,
Available online 4 March 2020.
撰 稿 者：
Philippe Colson
Jean-Marc Rolain
Jean-Christophe Lagier
Philippe Brouqui
Didier Raoult
原文连结：
https://www.sciencedirect.com/science/article/pii/
S0924857920300820?via%3Dihub#!
https://reurl.cc/yZnWpa
_______________________________________________
Chloroquine and hydroxychloroquine as available weapons to fight COVID-19
氯喹和羟氯喹可作为有效抵抗武汉肺炎的武器
Repositioning of drugs for use as antiviral treatments is a critical need.
使用既有的贮藏药品对于作为病毒性的治疗是一个急切的需要.
It is commonly very badly perceived by virologists, as we experienced when
reporting the effectiveness of azithromycin for Zika virus.
它通常非常慢的被病毒学家察觉, 像我们经历过的当时阿奇霉素有效于兹卡病毒的报告.
A response has come from China to the respiratory disease caused by the new
coronavirus (SARS-CoV-2) that emerged in December 2019 in this country.
2019 年 12 月一个来自中国对于呼吸道疾病导致由新的冠状病毒(SARS-CoV-2)发生在这
个国家.
Indeed, following the very recent publication of results showing the in vitro
activity of chloroquine against SARS-CoV-2, data have been reported on the
efficacy of this drug in patients with SARS-CoV-2-related pneumonia (named
COVID-19) at different levels of severity.
更确切的说, 紧接而来的最近发表的结果显示氯喹的实验性预防 SARS-CoV-2, 资料已经
报告出在药品对于患有 SARS-CoV-2 病人有关肺炎(名为武汉肺炎)在严重的不同程度等级
的效力.
Thus, following the in vitro results, 20 clinical studies were launched in
several Chinese hospitals.
如此, 紧接着在几个中国的医院 20 个临床研究下已经投入实验性的结果.
The first results obtained from more than 100 patients showed the superiority
of chloroquine compared with treatment of the control group in terms of
reduction of exacerbation of pneumonia, duration of symptoms and delay of
viral clearance, all in the absence of severe side effects.
第一个结果从超过 100 个病人显露出氯喹与肺炎恶化设法减少期限的控制群治疗法的比
较下是有优势的, 在持续的症状与病毒清除的延迟上, 全部都没有严重的副作用.
This has led in China to include chloroquine in the recommendations regarding
the prevention and treatment of COVID-19 pneumonia.
这在中国引进包括氯喹在关于预防和武汉肺炎的治疗上具有优势.
There is a strong rationality for the use of chloroquine to treat infections
with intracellular micro-organisms.
这里有一个强烈的理由在对于氯喹的使用上去治疗有关于细胞内微生物的传染病.
Thus, malaria has been treated for several decades with this molecule.
如此, 该分子用于疟疾治疗已有数十年.
In addition, our team has used hydroxychloroquine for the first time for
intracellular bacterial infections since 30 years to treat the intracellular
bacterium Coxiella burnetii, the agent of Q fever, for which we have shown in
vitro and then in patients that this compound is the only one efficient for
killing these intracellular pathogens.
此外, 我们的团队已使用羟氯喹在第一次在细胞内细菌性的感染从 30 年前去治疗细胞内
细菌贝氏考克斯菌, Q 型流感试剂, 为此我们展示了实验性和及时在病人上使用化合物是
唯一有效去杀除这些细胞外的病原体.
Since then, we have also shown the activity of hydroxychloroquine on
Tropheryma whipplei, the agent of Whipple's disease, which is another
intracellular bacterium for which hydroxychloroquine has become a reference
drug.
自此, 我们也展示了在 Tropheryma whipplei 上羟氯喹的活动力, Whipple's disease
的试剂是另一个细胞内的细菌为此羟氯喹可成为一个参考的药物.
Altogether, one of us (DR) has treated ~4000 cases of C. burnetii or T.
whipplei infections over 30 years (personal data).
总之, 在我们(医师)之中治疗到约 4000 案贝氏考克斯菌或 Tropheryma whipple 的感染
者超过 30 年(个人资料).
Regarding viruses, for reasons probably partly identical involving
alkalinisation by chloroquine of the phagolysosome, several studies have
shown the effectiveness of this molecule, including against coronaviruses
among which is the severe acute respiratory syndrome (SARS)-associated
coronavirus.
关于病毒, 有理由由吞解体的氯喹大概部分完全相同的需要碱化(这里可能要医学常识的
人来翻), 多项研究显示这个分子的效力, 包括对抗冠状病毒里是在这之中的非常严重急
性呼吸道并发症(SARS)-与之同类型冠状病毒.
We previously emphasised interest in chloroquine for the treatment of viral
infections in this journal, predicting its use in viral infections lacking
drugs.
我们在期刊上事先强调在氯喹用于病毒感染治疗上的重要性, 预料它为使用在病毒感染上
所欠缺的药品(lacking drugs?不太会翻).
Following the discovery in China of the in vitro activity of chloroquine
against SARS-CoV-2, discovered during culture tests on Vero E6 cells with 50%
and 90% effective concentrations (EC50 and EC90 values) of 1.13 μM and 6.90
μM, respectively (antiviral activity being observed when addition of this
drug was carried out before or after viral infection of the cells), we
awaited with great interest the clinical data.
紧接着在中国发现实验性氯喹对于对抗 SARS-CoV-2 的活动, 发现在培养测试 Vero E6
细胞于 1.13 uM 有效浓度 50 % 和 6.90 uM 有效浓度 90% (EC50 和 EC90 值)期间, 分
别地(抗病毒物质活动被观测到当添加这个药品时是可以在这细胞受病毒感染之前或之后
可被实现作用的), 我们期待对于临床有更重要价值的资料.
The subsequent in vivo data were communicated following the first results of
clinical trials by Chinese teams [4] and also aroused great enthusiasm among
us.
紧接而来在活的有机体内的资料是传染随着由中国团队临床试验的第一个结果且也唤起在
我们之中的重大的热忱.
They showed that chloroquine could reduce the length of hospital stay and
improve the evolution of COVID-19 pneumonia [4,6], leading to recommend the
administration of 500 mg of chloroquine twice a day in patients with mild,
moderate and severe forms of COVID-19 pneumonia.
他们显示氯喹可降低在医院停留时间且改善感染武汉肺炎发展, 主要地来说建议温和适中
和严重武汉肺炎症状的病人使用氯喹 500 mg 一天两次.
At such a dosage, a therapeutic concentration of chloroquine might be reached.
在这样的剂量, 一个氯喹的浓度治疗可能可以达到效果.
With our experience on 2000 dosages of hydroxychloroquine during the past 5
years in patients with long-term treatment (>1 year), we know that with a
dosage of 600 mg/day we reach a concentration of 1 μg/mL.
在我们经验中在过去 5 年中 2000次羟氯喹的剂量用在病人上随着长时间的治疗(大于 1
年), 我们知道在每天 600 mg的一个剂量我们可达到在 1 ug/mL 的浓度下.
The optimal dosage for SARS-CoV-2 is an issue that will need to be assessed
in the coming days.
对于 SARS-CoV-2 最理想的剂量那将会是需要在未来的日子里确定的一个论点.
For us, the activity of hydroxychloroquine on viruses is probably the same as
that of chloroquine since the mechanism of action of these two molecules is
identical, and we are used to prescribe for long periods hydroxychloroquine,
which would be therefore our first choice in the treatment of SARS-CoV-2.
对我们而言, 羟氯喹在病毒上的活动力是可能同样于氯喹而从这两个分子的功能结构是来
看是同样的, 且我们使用羟氯喹于处方已有很长时间, 因此我们在 SARS-CoV-2 的治疗上
使用羟氯喹是第一选择.
For optimal treatment, it may be necessary to administer a loading dose
followed by a maintenance dose.
对于最理想的治疗而言, 它可能必须要给予一个超负荷的剂量紧接着维持一个剂量.
___________________________________________________________
以上翻译有错请指证,
因为我不是读医的,
对于一些名词我不是很了解,
有的是从网络上查的.
另外目前中国是用磷酸氯喹在治疗,
国外有人用硫酸羟氯喹在治疗,
差别在于硫酸羟氯喹比磷酸氯喹便宜,
它是用在治疗关节问题上的.
但它不是疫苗,
它只是大幅减缓武汉肺炎的症状,
可以让你保命到疫苗研发出来为止.
至于服用的方式,
请跟医师和药剂师商量,
不要自己乱用.
__________________________________________
这个网址是比较完整的报告,
https://docs.google.com/document/d/e/
2PACX-1vTi-g18ftNZUMRAj2SwRPodtscFio7bJ7GdNgbJAGbdfF67WuR
JB3ZsidgpidB2eocFHAVjIL-7deJ7/pub?fbclid=IwAR3HXmAaRvsKQw
tD4mT0W6NU4bTJvZnR6f3KLRcsWkXSOGn33dbdR1KyS0Q
https://reurl.cc/MvZWKK
__________________________________________
伊隆·马斯克 Elon Musk推荐的, 网址点进去就是上面这个报告,
https://imgur.com/a/qw6qx7X